

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

October 21, 2015

MRI Interventions, Inc. % John J. Smith, MD, JD Partner Hogan Lovells US LLP Columbia Square 555 Thirteenth Street, NW Washington, DC 20004

Re: K142505

Trade/Device Name: ClearPoint System Regulation Number: 21 CFR 882.4560 Regulation Name: Stereotaxic Instrument

Regulatory Class: Class II Product Code: HAW, ORR Dated: September 22, 2015 Received: September 22, 2015

Dear Dr. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21)

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Carlos L. Pena -S

Carlos L. Peña, PhD, MS
Director
Division of Neurological
and Physical Medicine Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

510(k) Number (if known)	
K142505	
Device Name ClearPoint System	
Indications for Use (Describe)	
The ClearPoint System is intended to provide stereotactic guidance and operation of planning and operation of neurological procedures within the MRI environment and ClearPoint System is intended as an integral part of procedures that have traditional These procedures include biopsies, catheter and electrode insertion. The System is Tesla MRI scanners.	nd in conjunction with MR imaging. The ally used stereotactic methodology.
Type of Use (Select one or both, as applicable)	
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Cou	unter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary K142505

This 510(k) summary is being submitted in accordance with the requirements of 21 CFR Part 807.92 for the MRII ClearPoint System.

1. Company Making the Submission:

Name of Owner:	MRI Interventions, Inc.
Address:	5 Musick
	Irvine, CA 92618
Telephone:	949-900-6833
Fax:	949-900-6834
Contact:	Pete Piferi
E-mail:	ppiferi@mriinterventions.com
Date Prepared:	October 21, 2015

2. Device Name:

Common Name:	Neurological Stereotaxic
	Instrument
Proprietary Name:	ClearPoint System
Classification Name:	Stereotaxic Instrument
Regulatory Class:	II
Regulation Number:	21 C.F.R. § 882.4560
Product Code:	ORR, HAW

3. Predicate Device:

MRII ClearPoint System, K111073

4. Device Description:

The ClearPoint System is comprised of a workstation laptop with software, the SMARTGrid™ MRI-Guided Planning Grid, the SMARTFrame™ MRI-Guided Trajectory Frame, the SMARTFrame™ Accessory Kit and the SMARTFrame™ Hand Controller.

The SMARTGrid and associated Marking Tool are designed to assist the physician to precisely position the entry hole as called out in the trajectory planning software. The SMARTFrame is an Adjustable Trajectory Frame (ATF) that provides the guidance and fixation for neurosurgical tools. The MRI visible fluids of the Targeting Cannula along with the fiducial markers in the base of the frame allows for trajectory feedback when the physician views the MRI images, makes changes and confirms with subsequent MR images.

The ClearPoint System can be used with any MRI-compatible head fixation frame to immobilize the patient's head with respect to the scanner table, as well as with any imaging coil(s) that meet the physician's desired imaging quality. MRI Interventions also supplies an optional head fixation frame and imaging coil(s) that can be used with the ClearPoint System.

The ClearPoint Workstation includes the following:

- 1. ClearPoint Workstation Software (for trajectory planning and monitoring)
- 2. Laptop Computer

The hardware components of the ClearPoint System are the SMARTFrame and Accessories. They are all single use devices that are provided sterile. They include the following:

- 1. SMARTGrid Pack (interacts with the software to determine the desired location of the burr hole)
 - a. Marking Grid
 - b. Marking Tool
- 2. SMARTFrame Pack (SMARTFrame or SMARTFrame XG)
 - a. SMARTFrame ("ATF") with Base
 - b. Centering Tool
 - c. Dock
 - d. Device Lock (2 different diameters)
 - e. Screwdriver
 - f. Roll Lock Screw and Washer
- 3. Rescue Screws (Extra Titanium Screws)
- 4. Hand Controller (for use with the ATF) and Thumbwheel Extension
- 5. Accessory Pack
 - a. Peel-away Sheath
 - b. Stylet
 - c. Lancet
 - d. Depth Stop
 - e. Ruler
- 6. Scalp Mount Base
- 7. Guide Tube and Device Guide Packs (Guide Cannulas)
- 8. SmartTip MRI Hand Drill and Drill Bit Kit
- 9. MRI Neuro Procedure Drape, with Marker Pen and Cover
- 10. MR Camera Fiberscope Accessory Kit
- 11. SmartFrame MR Fiducial

Each of the above packs is sold separately. Each is intended to be used with the ClearPoint Workstation.

5. Indications for Use:

The ClearPoint System is intended to provide stereotactic guidance and operation of instruments or devices during the planning and operation of neurological procedures within the MRI environment and in conjunction with MR imaging. The ClearPoint System is intended as an integral part of procedures that have traditionally used stereotactic methodology. These procedures include biopsies, catheter and electrode insertion. The System is intended for use only with 1.5 and 3.0 Tesla MRI scanners.

6. Comparison of the Technological Characteristics of the Device with the Predicate Device:

Modifications to the predicate ClearPoint System are as follows:

- a) The Scalp Mount is a modified base for the existing ClearPoint ATF allowing attachment through the scalp to the skull instead of directly to the skull via a relatively large incision.
- b) The SMARTFrame XG is a modified tower of the ClearPoint ATF allowing the exchange of Guide Cannulas, e.g. removal of the existing Guide Cannula and replacement with a Guide Cannula(s), allowing larger devices to be utilized in neurological procedures.

- c) Evolutionary changes within the ClearPoint System software.d) Minor modifications of pre-existing accessories for the ClearPoint System.

	ClearPoint System K111073	ClearPoint System (Modified)	
Classification	21 CFR 882.4560	21 CFR 882.4560	
Product Code	ORR, HAW	ORR, HAW	
Intended Use	The ClearPoint System is intended to	The ClearPoint System is intended to	
	provide stereotactic guidance and	provide stereotactic guidance and	
	operation of instruments or devices	operation of instruments or devices	
	during the planning and operation of	during the planning and operation of	
	neurological procedures within the	neurological procedures within the	
	MRI environment and in conjunction	MRI environment and in conjunction	
	with MR imaging. The ClearPoint System is intended as an integral part	with MR imaging. The ClearPoint System is intended as an integral part	
	of procedures that have traditionally	of procedures that have traditionally	
	used stereotactic methodology.	used stereotactic methodology.	
	These procedures include biopsies,	These procedures include biopsies,	
	catheter and electrode insertion. The	catheter and electrode insertion. The	
	System is intended for use only with	System is intended for use only with	
	1.5 and 3.0 Tesla MRI scanners.	1.5 and 3.0 Tesla MRI scanners.	
Environment Sterilization	MRI Suite	MRI Suite	
	EO 10 ⁻⁶ SAL	EO 10 ⁻⁶ SAL	
SmartGrid Pack	MRI Planning Grid & Marking Tool	MRI Planning Grid & Marking Tool	
SmartFrame		SmartFrame XG, Scalp Mount Base,	
Pack	SmartFrame ATF, Scalp Mount Base,	Bone Screws, Scalp Mount Base,	
	Bone Screws, Screwdriver, Centering Tool, Dock and Lock, Roll Lock Screw	Screws, Stand-Off Pins, Screwdriver, Centering Tool, Dock and Lock, Roll	
	with Washer, Extra Titanium Screws	Lock Screw with Washer, Rescue	
	With Washer, Extra Filamani Solows	Screws (packaged separately)	
Hand	Lland Cantrollar	Thumbwheel Extension (Light Hand	
Controller	Hand Controller	Controller)	
Accessory Kit	Peel-away Sheath, Stylet, Depth	Peel-away Sheath, Lancet, Stylet,	
	Stop, Ruler	Depth Stop, Ruler	
Targeting Cannula ID	0.0825"	0.0825"	
Targeting			
Cannula	Ultem and PEEK	Ultem and PEEK	
Material			
Guide Tube /	0.050.0000.0074	0.0000 0.0444"	
Device Guide ID	0.052, 0.068, 0.074"	0.0938 & 0.141"	
Guide Tube /			
Device Guide	Ultem and PEEK	Ultem and PEEK	
Material			
Packaging	Sterile, Sealed Tray, Inside Sterile	Sterile, Sealed Tray, Inside Sterile	
	Tyvek Pouch	Tyvek Pouch	
Targeting	±1.5mm @ ≤125mm	±1.5mm @ ≤125mm	
Accuracy			
Software	1.0	1.5	

The Scalp Mount Base performs exactly the same function as the original SmartFrame Base, but is mounted through the patient's scalp to the skull instead of

directly to the scalp via a relatively large incision. The modification to the original Base was made to allow less invasive procedures to be performed with the SmartFrame.

The SmartFrame XG is a modification to the previously cleared SmartFrame ATF that is sold as a separate product. The need for the SmartFrame XG arose from physicians' desire to use ClearPoint and the SmartFrame for precision placement of MRI Compatible Biopsy Needles, Shunt Catheters for cyst drainage, and laser ablation catheters. The changes had no impact on use of the SmartFrame. The same Dock-and-Lock system used in the original SmartFrame ATF can be used with the SmartFrame XG. No software changes were necessary for the SmartFrame XG. The SmartFrame XG is fully interchangeable with all other SmartFrame components and accessories.

7. Performance Data:

The performance testing performed for the predicate ClearPoint System (K111073) is fully applicable to the modified ClearPoint System performance. Specifically, the following testing that was performed on the predicate device is fully applicable to the modified ClearPoint System:

- Accuracy Testing, including MRI Device Accuracy Testing, System Accuracy
 in a Water Phantom and System Accuracy in a Cadaver. These test results
 demonstrate the targeting accuracy of the predicate ClearPoint System
 (K111073) when used in conjunction with MRI scanner software. The results
 support the safe and effective use of the ClearPoint System to guide a device
 to a brain target with an error less than 1.5mm at ≤125mm.
- ClearPoint System Safety Testing with 1.5T and 3.0T MRI scanners.

In addition, the accuracy testing for the predicate ClearPoint System (K111073) was repeated for the modified ClearPoint System to validate a targeting accuracy for the ClearPoint System using the raised Scalp Mount frame. The results of this testing confirm the targeting accuracy of the device with an error less than 1.5mm at ≤125mm from the insertion point.

No additional sterility testing was performed. Additional biocompatibility tests were performed on the Device Guides as described below.

The ClearPoint System was modified in conformance with the company's design control procedures. Design inputs provided the requirements for the respective product specifications. Design Verification was performed relative to these specifications with acceptable results. Risk analysis was performed with mitigation of all identified risks to acceptable levels. The tests and risk analysis demonstrated that the modified ClearPoint System functions as intended and is substantially equivalent to the legally marketed ClearPoint System. A summary of the performance testing that was conducted on the subject device is presented in the table below.

The risks of the modified ClearPoint System were further mitigated through labeling revisions to include a warning that end users should not use the system with instruments longer than 30cm in length, as the accuracy of the system has not been established with instruments longer than this length.

Test	Test Method Summary	Results
Accuracy of Scalp Mount	The Scalp Mount Base was tested using a water	Pass
Base	phantom to verify system accuracy was maintained.	
Accuracy of Large Bore ATF	A cadaver study was used to verify the accuracy of	Pass
and Device Guide	the Large Bore ATF and Device Guide.	
Accuracy of SmartFrame XG	The SmartFrame XG and Device Guides were	Pass
and Device Guides	verified to maintain accuracy using a photomapping	
	digitizer program and a cylindrical phantom test.	
Accuracy of ClearPoint	Accuracy of the system under adverse and worst	Pass
Components, Assemblies	case conditions evaluated to ensure Stylet location	
and System	was maintained.	
Targeting Cannula Aging	One- and two-year accelerated heat aging tests for	13-Month
	the Targeting Cannula	Shelf Life
Biocompatibility of Device	Cytotoxicity Study Using ISO Elution Method & ISO	Pass
Guide	Skin Irritation Study in Rabbits	

Software Verification and Validation

Software verification and validation testing was conducted and documentation was provided as recommended by FDA's Guidance for industry and FDA Staff, "Guidance for the content of premarket Submission for software Contained in Medical Devices." The software for this device represents a moderate level of concern. The system conforms to the DICOM standard to allow the transfer of images from the MR scanner.

Consensus Standards

The ClearPoint System complies with the following recognized consensus standards:

- NEMA PS 3.1-3.18 (2008) Digital Imaging and Communications in Medicine (DICOM) Set
- AAMI/ANSI/ISO 10993-1 Biological evaluation of medical devices Part 1: Evaluation and testing.
- ANSI/AAMI/ISO 1135-1 Sterilization of health care products Ethylene oxide Part
 1: Requirements for development, validation, and routine control of sterilization process for medical devices.

8. Conclusions:

The modifications to the ClearPoint System were made in conformance with the company's design control procedures and the performance testing performed for the predicate ClearPoint System (K111073), including accuracy testing and safety testing, is fully applicable to the modified ClearPoint System. Additional accuracy testing was performed with the raised Scalp Mount base to confirm the accuracy of the modified device with an error less than 1.5mm at ≤125mm from the insertion point.

The modified ClearPoint System has the same intended use and indications for use and similar technologies characteristics and principles of operation as the predicate ClearPoint System. The minor technological differences between the modified ClearPoint System and its predicate ClearPoint System raise no new issues of safety and effectiveness. Thus the modifications are substantially equivalent to the previously cleared ClearPoint System.